SOURCE: Milestone Scientific, Inc.

Milestone Scientific

August 17, 2015 10:28 ET

Milestone Conducts Preliminary Study of Its Computer-Controlled Injection and Drug Delivery Instrument at the Cornell University College of Veterinary Medicine

LIVINGSTON, NJ--(Marketwired - August 17, 2015) - Milestone Scientific Inc. (NYSE MKT: MLSS) today announced that Cornell University College of Veterinary Medicine completed a preliminary study of its computer-controlled injection and drug delivery technology. The study was conducted by Dr. Luis Campoy, Associate Clinical Professor in Anesthesiology and Analgesia. The study concluded that Milestone's instrument appears to have high sensitivity to detect an important target when performing a maxillary nerve block for an equine (horse) application. The study concluded that the instrument has potential beyond a specific application and may be used as a training tool for clinicians learning to perform some locoregional injections in which having tissue tactile feedback is of paramount importance (e.g. epidural injection in dogs, retrobulbar injections in horses).

Milestone's patented technology regulates and controls the flow rate of fluid, minimizing tissue damage and allowing for painless injections. The Dynamic Pressure Sensing® (DPS) capability provides visual and audible in-tissue pressure feedback. DPS provides medical practitioners with the ability to identify pressure signatures for the different tissue types and inject drugs at precisely the right location, eliminating guesswork. Additionally, the disposable injection handpiece allows for precise tactile control during an injection.

Leonard Osser, CEO of Milestone Scientific Inc., commented, "We are pleased to report the findings of this preliminary study on equine specimens, which demonstrated the validity of using Milestone's DPS technology for the loss of resistance technique, and further validates the potential of our instrument in veterinary applications. This study was a first step towards defining the proof of principle that our technology is capable of successfully performing veterinary injections."

Dr. Luis Campoy, Associate Clinical Professor in Anesthesiology and Analgesia, commented, "This initial study confirmed our expectations, and there is reason to believe the instrument will be equally effective in clinical practice. We look forward to conducting further research in a clinical setting, comparing with the standard techniques for equine injections. Presently, the standard techniques used to administer a maxillary foramen block in the horse have the potential to cause trauma and laceration of sensitive anatomical structures including arteries, veins and nerves situated in the vicinity the target location. We have developed a new technique at Cornell that addresses these risks, but is difficult to train practitioners and bring objectivity. Milestone's instrument has the potential to overcome these challenges by providing precise measurement of tactile feedback utilizing the new technique."

About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website:

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact Information

  • Contact:
    David Waldman or Klea Theoharis
    Crescendo Communications, LLC
    Tel: 212-671-1020